Paradigm Shift in Ovarian Cancer Points to Fallopian Tube as Site of Origin

article

.....The decade-long paradigm shift in decoding ovarian cancer is only now beginning to make its way from research journals into clinical practice.
These changes will have a tremendous effect on the management of ovarian cancer, which is still treated as a single disease.
That's the conclusion of Ronny Drapkin, MD, PhD, the Franklin Payne Chair in Gynecologic Oncology and director of the Penn Ovarian Cancer Research Center at the University of Pennsylvania Perelman School of Medicine in Philadelphia......

....Pointing out that only 59% of cases of ovarian cancer are detected by screening plus ultrasound, “we must and can focus on mechanisms of early cancer detection,” René H M Verheijen and Ronald P. Zweemer, of the Department of Gynaecological Oncology, Division of Surgical Oncology, UMC Utrecht Cancer Center, Utrecht, Netherlands, commented in The Lancet regarding the UKCTOCS trial.³
However, “awareness and symptom recognition for diagnosis of ovarian cancer at an early stage will be difficult to improve upon,” they wrote, adding that “screening will not be warranted until the UKCTOCS outcome has been validated in daily practice.”

References

1. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945-956.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
3. Verheijen RHM, Zweemer RP. Screening to improve ovarian cancer prognosis? Lancet. 2016;387(10022):921-923.